BridgeMD
Tests treatment safety and results for BPD - Bronchopulmonary Dysplasia
Official title Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stem Cell(MSC) Transplantation in the Treatment of Bronchopulmonary Dysplasia(BPD) in Premature Infants
ClinicalTrials.gov ID: NCT06788470
What this study is testing
What is MSC?
MSC is an investigational medicine, being studied as a potential treatment for bpd - bronchopulmonary dysplasia.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Bronchopulmonary dysplasia (BPD) is a chronic lung disease, which is a major complication of very low and ultra-low preterm infants. Moderate and severe BPD survivors are prone to adverse outcomes such as impaired lung function, childhood exercise intolerance, and neurodevelopmental retardation in the long term, which seriously affects their quality of life and brings a heavy burden to society and families.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 36 and older
You may be able to join if
- 23-29 weeks of gestation, birth weight 500-1500g;
- For patients with no improvement or aggravation of lung condition after DART hormone therapy, and positive pressure ventilation by tracheal...
- Children with severe BPD after early use of PS
- Parents agree to participate in clinical trials.
You likely can't join if
- Premature infants not suitable for the given gestational age;
- Other congenital structural malformations of trachea, bronchus and lungs;
- Complicated with severe congenital heart disease;
- Complicated with Periventricular Leukomalacia (PVL);
- Complicated with intraventricular hemorrhage (IVH) above level 3;
- Septic shock or positive blood culture;
See the full eligibility criteria
- 23-29 weeks of gestation, birth weight 500-1500g;
- For patients with no improvement or aggravation of lung condition after DART hormone therapy, and positive pressure ventilation by tracheal intubation is still required at a correct gestational age of 36 weeks.
- Children with severe BPD after early use of PS
- Parents agree to participate in clinical trials.
- Premature infants not suitable for the given gestational age;
- Other congenital structural malformations of trachea, bronchus and lungs;
- Complicated with severe congenital heart disease;
- Complicated with Periventricular Leukomalacia (PVL);
- Complicated with intraventricular hemorrhage (IVH) above level 3;
- Septic shock or positive blood culture;
- Acute pulmonary hemorrhage;
- Intracranial and extracranial diseases affecting respiratory rate and rhythm.
The study team makes the final eligibility decision.
Where it's taking place
- Hangzhou, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 36 weeks and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hangzhou, Zhejiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.